{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:38:59Z","timestamp":1787989139874,"version":"build-2784847793"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,28]]},"DOI":"10.7759\/cureus.102472","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T14:49:16Z","timestamp":1769611756000},"source":"Crossref","is-referenced-by-count":2,"title":["Investigating the Link Between Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Non-arteritic Ischemic Optic Neuropathy: A Case Report of Semaglutide-Induced Optic Neuropathy"],"prefix":"10.7759","author":[{"given":"Mashair","family":"Bakheet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attiqa","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/vision7040072","article-title":"Non-arteritic anterior ischemic optic neuropathy (NA-AION): a comprehensive overview","volume":"7","author":"Salvetat ML","year":"2023","unstructured":"Salvetat ML, Pellegrini F, Spadea L, Salati C, Zeppieri M. Non-arteritic anterior ischemic optic neuropathy (NA-AION): a comprehensive overview. Vision (Basel). 2023, 7:72. 10.3390\/vision7040072","journal-title":"Vision (Basel)"},{"key":"ref2","article-title":"Nonarteritic anterior ischemic optic neuropathy","author":"Kaur K","year":"2025","unstructured":"Kaur K, Margolin E. Nonarteritic anterior ischemic optic neuropathy. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073451","article-title":"Glucagon-like peptide-1 receptor agonists in the management of type 2 diabetes mellitus and obesity: the impact of pharmacological properties and genetic factors","volume":"23","author":"Klen J","year":"2022","unstructured":"Klen J, Dol\u017ean V. Glucagon-like peptide-1 receptor agonists in the management of type 2 diabetes mellitus and obesity: the impact of pharmacological properties and genetic factors. Int J Mol Sci. 2022, 23:3451. 10.3390\/ijms23073451","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13361","article-title":"Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"20","author":"Andreadis P","year":"2018","unstructured":"Andreadis P, Karagiannis T, Malandris K, et al.. Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2018, 20:2255-63. 10.1111\/dom.13361","journal-title":"Diabetes Obes Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.645563","article-title":"Safety of semaglutide","volume":"12","author":"Smits MM","year":"2021","unstructured":"Smits MM, Van Raalte DH. Safety of semaglutide. Front Endocrinol (Lausanne). 2021, 12:645563. 10.3389\/fendo.2021.645563","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/aos.17473","article-title":"Semaglutide and non-arteritic anterior ischaemic optic neuropathy: review and interpretation of reported association","volume":"103","author":"Amini A","year":"2025","unstructured":"Amini A, Hamann S, Larsen M. Semaglutide and non-arteritic anterior ischaemic optic neuropathy: review and interpretation of reported association. Acta Ophthalmol. 2025, 103:615-21. 10.1111\/aos.17473","journal-title":"Acta Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway JT","year":"2024","unstructured":"Hathaway JT, Shah MP, Hathaway DB, et al.. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 2024, 142:732-9. 10.1001\/jamaophthalmol.2024.2296","journal-title":"JAMA Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01366-8","article-title":"GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs","volume":"20","author":"Giugliano D","year":"2021","unstructured":"Giugliano D, Scappaticcio L, Longo M, et al.. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021, 20:189. 10.1186\/s12933-021-01366-8","journal-title":"Cardiovasc Diabetol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16316","article-title":"Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: a Danish-Norwegian cohort study","volume":"27","author":"Simonsen E","year":"2025","unstructured":"Simonsen E, Lund LC, Ernst MT, et al.. Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: a Danish-Norwegian cohort study. Diabetes Obes Metab. 2025, 27:3094-103. 10.1111\/dom.16316","journal-title":"Diabetes Obes Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2025.0349","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy risk among patients with diabetes","volume":"143","author":"Hsu AY","year":"2025","unstructured":"Hsu AY, Kuo HT, Wang YH, et al.. Semaglutide and nonarteritic anterior ischemic optic neuropathy risk among patients with diabetes. JAMA Ophthalmol. 2025, 143:400-7. 10.1001\/jamaophthalmol.2025.0349","journal-title":"JAMA Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2011.02.003","article-title":"Nonarteritic anterior ischemic optic neuropathy (NAION) and its experimental models","volume":"30","author":"Bernstein SL","year":"2011","unstructured":"Bernstein SL, Johnson MA, Miller NR. Nonarteritic anterior ischemic optic neuropathy (NAION) and its experimental models. Prog Retin Eye Res. 2011, 30:167-87. 10.1016\/j.preteyeres.2011.02.003","journal-title":"Prog Retin Eye Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/460288-investigating-the-link-between-glucagon-like-peptide-1-glp-1-receptor-agonists-and-non-arteritic-ischemic-optic-neuropathy-a-case-report-of-semaglutide-induced-optic-neuropathy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T14:49:17Z","timestamp":1769611757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/460288-investigating-the-link-between-glucagon-like-peptide-1-glp-1-receptor-agonists-and-non-arteritic-ischemic-optic-neuropathy-a-case-report-of-semaglutide-induced-optic-neuropathy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.102472","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,28]]}}}